Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older

Vaccine

Volumn 27, Issue 4, 2009, Pages 520-529

  Stein, Alicia N ^a   Britt, Helena ^b   Harrison, Christopher ^b   Conway, E Lynne ^a   Cunningham, Anthony ^c   MacIntyre, C Raina ^d  

^a CSL LIMITED   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Burden of illness; Health care costs; Herpes zoster; Post herpetic neuralgia

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CAPSAICIN; CARBAMAZEPINE; CORTICOSTEROID; DEXTROPROPOXYPHENE PLUS PARACETAMOL; FAMCICLOVIR; GABAPENTIN; OXYCODONE; PARACETAMOL; TRAMADOL; VALACICLOVIR; VARICELLA ZOSTER VACCINE; ZINC DERIVATIVE;

ADULT; AGED; ARTICLE; AUSTRALIA; CONSULTATION; COST OF ILLNESS; EMERGENCY WARD; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INCIDENCE; MORBIDITY; POSTHERPETIC NEURALGIA; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AUSTRALIA; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HEALTH STATUS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED;

EID: 57749173134     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.012     Document Type: Article

References (50)

1. Wareham D.W., and Breuer J. Herpes zoster. BMJ 334 7605 (June 9) (2007) 1211-1215
2. Brisson M., and Edmunds W.J. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 70 Suppl 1 (2003) S9-S14
3. Edmunds W.J., Brisson M., and Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19 23-24 (April 30) (2001) 3076-3090
4. Insinga R.P., Itzler R.F., Pellissier J.M., Saddier P., and Nikas A.A. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 20 8 (August) (2005) 748-753
5. Opstelten W., Mauritz J.W., de Wit N.J., van Wijck A.J., Stalman W.A., and van Essen G.A. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 19 5 (October) (2002) 471-475
6. Mullooly J.P., Riedlinger K., Chun C., Weinmann S., and Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 133 2 (April) (2005) 245-253
7. Schmader K.E., and Dworkin R.H. Natural history and treatment of herpes zoster. J Pain 9 1 Suppl 1 (January) (2008) S3-S9
8. Hope-Simpson R.E. Postherpetic neuralgia. J R Coll Gen Pract 25 157 (August) (1975) 571-575
9. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 22 (June 2) (2005) 2271-2284
10. Johnson R.W. Herpes zoster-predicting and minimizing the impact of post-herpetic neuralgia. J Antimicrob Chem 47 (2001) 1-8
11. Kost R.G., and Straus S.E. Postherpetic neuralgia-pathogenesis, treatment, and prevention. N Engl J Med 335 1 (July 4) (1996) 32-42
12. Gauthier A., Breuer J., Carrington D., Martin M., and Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect (2008 May 9) 1-10
13. Merck S&DA. ZOSTAVAX zoster virus vaccine live (Oka/Merck) MSD refrigerator stable (ZST/R-I-112007) Product Information. TGA approved September 12, 2007; Date of most recent ammendment January 7, 2008. CSL Biotherapies; 2008. Available from: URL: http://secure.healthlinks.net.au/content/csl/pi.cfm?product=cspzosta10708.
14. Kerzner B., Murray A.V., Cheng E., Ifle R., Harvey P.R., Tomlinson M., et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 55 10 (October) (2007) 1499-1507
15. Gilderman L.I., Lawless J.F., Nolen T.M., Sterling T., Rutledge R.Z., Fernsler D.A., et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of ZOSTAVAX(R). Clin Vaccine Immunol 15 2 (December 12) (2008) 314-319
16. Australian Technical Advisory Group on Immunisation (ATAGI). Systematic review of safety, immunogenicity and efficacy of zoster vaccines. Australian Government Department of Health and Ageing; 2008. Available from: URL: http://www.immunise.health.gov.au.
17. Zostavax European Public Assessment Report; 2008 September 22.
18. Harpaz R., Ortega-Sanchez I., and Seward J. Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR 57 5 (June 6) (2008) 1-30
19. Mueller N.H., Gilden D.H., Cohrs R.J., Mahalingam R., and Nagel M.A. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin 26 3 (August) (2008) 675-697
20. Gidding H.F., MacIntyre C.R., Burgess M.A., and Gilbert G.L. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect 131 3 (December) (2003) 1085-1089
21. NHMRC. Australian Immunization Handbook, 9th edition. Australian Government Department of Health and Ageing; 2008 January 1. Available from: URL: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-home.
22. MacIntyre C.R., Chu C.P., and Burgess M.A. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect 131 1 (August) (2003) 675-682
23. Chant K.G., Sullivan E.A., Burgess M.A., Ferson M.J., Forrest J.M., Baird L.M., et al. Varicella-zoster virus infection in Australia. Aust NZ J Public Health 22 4 (June) (1998) 413-418
24. Britt H., Miller G.C., Charles J., Pan Y., Valenti L., Henderson J., et al. General practice activity in Australia 2005-06 (2007), Australian Institute for Health and Welfare, Canberra Report No.: 19
25. Classification Committee of the World Organization of Family Doctors (WICC). ICPC-2: International classification of primary care. 2nd ed. (1998), Oxford University Press, Oxford
26. Britt H. A new coding tool for computerised clinical systems in primary care-ICPC plus. Aust Fam Physician 26 Suppl 2 (July) (1997) S79-S82
27. Anatomic Therapeutic Chemical (ATC) Classification. The WHO Collaborating Centre for Drug Statistics Methodology; 2007. Available from: URL: http://www.whocc.no/atcddd/.
28. Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 127 2 (October) (2001) 305-314
29. Fleming D.M., Bartelds A., Chapman R.S., and Cross K.W. The consistency of shingles and its significance for health monitoring. Eur J Epidemiol 19 12 (2004) 1113-1118
30. Medicare Benefits Schedule (MBS) statistics reports. Medicare Australia; 2007. Available from: URL: http://www.medicareaustralia.gov.au/providers/health_statistics/statistical_reporting.htm.
31. Australian Bureau of Statistics. Series B projections by age and sex. Australian Bureau of Statistics; 2007. Available from: URL: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3222.02004%20to%202101?OpenDocument.
32. Pharmaceutical Benefits Schedule Item Statistics. Medicare Australia; 2007. Available from: URL: http://www.medicareaustralia.gov.au/statistics/dyn_pbs/forms/pbs_tab1.shtml.
33. Interactive national hospital morbidity data (data cubes). Australian Institute of Health and Welfare; 2007. Available from: URL: http://www.aihw.gov.au/hospitals/datacubes/index.cfm.
34. Casemix Data Collections. Round 9 (2004-05) Cost report version 5.0. Department of Health and Aging; 2007. Available from: URL: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/+Round_9-cost-reports.
35. Medicare Australia. Medicare Benefits Schedule (MBS) online. Australian Government Department of Health and Aging; 2007. Available from: URL: http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1.
36. Dworkin R.H., Johnson R.W., Breuer J., Gnann J.W., Levin M.J., Backonja M., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 44 Suppl 1 (January 1) (2007) S1-S26
37. Cunningham A.L., Breuer J., Dwyer D.E., Gronow D.W., Helme R.D., Litt J.C., et al. The prevention and management of herpes zoster. Med J Aust 188 3 (February 4) (2008) 171-176
38. Schedule of Pharmaceutical Benefits. Department of Health and Aging; 2007. Available from: URL: http://www.pbs.gov.au/html/home.
39. Pharmacy Direct; 2007. Available from: URL: http://www.pharmacydirect.com.au/.
40. Scott F.T., Johnson R.W., Leedham-Green M., Davies E., Edmunds W.J., and Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 24 9 (February 27) (2006) 1308-1314
41. Chidiac C., Bruxelle J., Daures J.P., Hoang-Xuan T., Morel P., Leplege A., et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 33 1 (July 1) (2001) 62-69
42. van Wijck A.J., Opstelten W., Moons K.G., van Essen G.A., Stolker R.J., Kalkman C.J., et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 367 9506 (January 21) (2006) 219-224
43. Helgason S., Petursson G., Gudmundsson S., and Sigurdsson J. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long-term follow-up. Br Med J 321 7264 (2000) 794
44. De Moragas, and Kierland R. The outcome of patients with herpes zoster. AMA Arch Derm 75 2 (February) (1957) 193-196
45. Dworkin R.H., White R., O'Connor A.B., Baser O., and Hawkins K. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 55 8 (August) (2007) 1168-1175
46. Yawn B.P., Saddier P., Wollan P.C., St Sauver J.L., Kurland M.J., and Sy L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82 11 (November) (2007) 1341-1349
47. Saddier P., Sy L., Nikas A., Holmes R., Rajagopal G., Whipple M., et al. Herpes zoster hospitalizations in the United States. Proceedings of the 44th annual meeting of the infectious disease society of America (2006) 191
48. Insinga R.P., Itzler R.F., and Pellissier J.M. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 25 2 (2007) 155-169
49. Johnson R.W. Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes 10 2 (August) (2003) 38-45
50. Opstelten W., van Loon A.M., Schuller M., van Wijck A.J., van Essen G.A., Moons K.G., et al. Clinical diagnosis of herpes zoster in family practice. Ann Fam Med 5 4 (July) (2007) 305-309